Press release Biocartis Group NV: Disclosure of transparency notifications
09 Dezember 2022 - 5:40PM
Press release Biocartis Group NV: Disclosure of transparency
notifications
PRESS RELEASE: REGULATED INFORMATION
9
December 2022, 17:40 CET
Disclosure of transparency
notifications
Mechelen,
Belgium, 9
December 2022 – Biocartis Group
NV (the ‘Company’ or ‘Biocartis’), an innovative molecular
diagnostics company (Euronext Brussels: BCART), announces today, in
accordance with Article 14, paragraph 1 of the Belgian Act of
2 May 2007 on the disclosure of major shareholdings in issuers of
which shares are admitted to trading on a regulated market and
laying down miscellaneous provisions (the ‘Belgian Transparency
Act’), that it received the following transparency
notifications:
1) A transparency notification
dated 7 December 2022 indicating that on 2 December 2022 the
shareholding of the Belgian State (through
SFPI-FPIM or Société Fédérale de Participations et
d'Investissement - Federale Participatie- en
Investeringsmaatschappij) has crossed the 5% notification
threshold. The notification contains the following information:
- Reason for the notification: Acquisition or disposal of voting
securities or voting rights.
- Notification by: A parent undertaking or a controlling
person.
- Person subject to the notification requirement: SFPI-FPIM,
Avenue Louise 32 box 4, 1050 Brussels, Belgium; Belgische
Staat/Etat belge, Wetstraat 12 and Koloniënstraat 11, 1000
Brussels, Belgium.
- Transaction date: 2 December 2022.
- Threshold that is crossed: 5%.
- Denominator: 92,061,563.
- Details of the notification: The notification sets out that it
concerns an upward crossing of the 5% notification threshold. On
the date of the notification, SFPI-FPIM held 7.29% of the voting
rights in Biocartis.
- Full chain of controlled undertakings through which the holding
is effectively being held: SFPI-FPIM is 100% controlled by the
Belgian State.
2) A transparency notification
dated 7 December 2022 indicating that on 2 December 2022 the
shareholding of the Flemish Region (through
ParticipatieMaatschappij Vlaanderen NV or PMV
NV) has decreased below the 3% notification
threshold. It concerns a passive downward crossing of the lowest
notification threshold. The notification contains the following
information:
- Reason for the notification: Downward crossing of the lowest
threshold. Passive crossing of a threshold.
- Notification by: A parent undertaking or a controlling
person.
- Person subject to the notification requirement: Vlaams Gewest,
Havenlaan 88, 1000 Brussels, Belgium; PMV NV, Oude Graanmarkt 63,
1000 Brussels, Belgium.
- Transaction date: 2 December 2022.
- Threshold that is crossed: 3%.
- Denominator: 92,061,563.
- Details of the notification: The notification sets out that it
concerns a passive downward crossing of the lowest (3%)
notification threshold. On the date of the notification, the
Flemish Region (through PMV NV) had an aggregate position of
2.54%.
- Full chain of controlled undertakings through which the holding
is effectively being held: The Flemish Region (Vlaams Gewest)
controls and owns 100% of the shares in PMV NV.
- Additional information: Downward crossing of the lowest
threshold/Passive downward crossing due to dilution - PMV decided
not to subscribe to capital increase. Recent review has shown that
the notification from 21 February 2018 regarding the number of
shares held by PMV NV in Biocartis was not completely accurate. PMV
NV held 501,484 shares instead of the stated 428,000 shares. This
brought the total number of shares held at that moment to 2,342,345
shares instead of 2,268,861 shares.
3) A transparency notification
dated 7 December 2022 indicating that on 2 December 2022 the
aggregate number of voting rights and equivalent financial
instruments held by Credit Suisse
(Schweiz) AG, a subsidiary of Credit Suisse Group
AG, decreased to 1.68%, as further explained below. On the date of
the notification, Credit Suisse Group AG, the parent company, held
an aggregate position of 3.61% (as compared to 3.62% notified to
Biocartis on 29 November 2022). The notification contains the
following information:
- Reason for the notification: Acquisition or disposal of voting
securities or voting rights.
- Notification by: A parent undertaking or a controlling
person.
- Person subject to the notification requirement: Credit Suisse
Group AG, Paradeplatz 8, CH-8001 Zürich, Switzerland.
- Transaction date: 2 December 2022.
- Threshold that is crossed: 3%.
- Denominator: 92,061,563.
- Details of the notification: The notification sets out that it
concerns a group notification with a downward crossing of the 3%
threshold at the level of the subsidiary Credit Suisse (Schweiz)
AG. On the date of the notification, this entity held an aggregate
position of 1.68% of voting rights and equivalent financial
instruments (i.e., shares which it has out on loan to third parties
with a right to recall) as compared to 3.20% notified to Biocartis
on 29 November 2022. Together with the participation of 1.93% of
Credit Suisse Fund Management S.A., another subsidiary of
Credit Suisse Group AG, the latter held an aggregate position of
3.61% (as compared to 3.62% notified to Biocartis on 29 November
2022).
- Full chain of controlled undertakings through which the holding
is effectively being held: Credit Suisse Group AG, Credit Suisse
AG, Credit Suisse Asset Management International Holding Ltd.,
Credit Suisse Asset Management & Investor Service (Schweiz)
Holding AG, Credit Suisse Fund Management S.A./ Credit Suisse Group
AG, Credit Suisse AG, Credit Suisse (Schweiz) AG.
4) A transparency notification
dated 8 December 2022 indicating that on 2 December 2022 the
shareholding of Johnson & Johnson
Innovation - JJDC, Inc., a subsidiary of Johnson &
Johnson, has decreased below the 5% notification threshold. It
concerns a passive downward crossing of the 5% threshold. The
notification contains the following information:
- Reason for the notification: Passive crossing of a
threshold.
- Notification by: A parent undertaking or a controlling
person.
- Person subject to the notification requirement: Johnson &
Johnson, 1 J&J Plaza, New Brunswich, New Jersey, 08901 United
States of America; Johnson & Johnson Innovation - JJDC, Inc.,
410 George Street, New Brunswich, New Jersey, 08901, United States
of America.
- Transaction date: 2 December 2022.
- Threshold that is crossed: 5%.
- Denominator: 92,061,563.
- Details of the notification: The notification sets out that it
concerns a passive downward crossing of the 5% notification
threshold. On the date of the notification, Johnson & Johnson
Innovation - JJDC, Inc. had an aggregate position of 4.18%.
- Full chain of controlled undertakings through which the holding
is effectively being held: Johnson & Johnson Innovation - JJDC,
Inc. is a wholly owned subsidiary of Johnson & Johnson. Johnson
& Johnson is not a controlled entity.
For further information, reference is made to
the notifications which are available here on the Biocartis
website.
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the
Company and the Belgian Financial Services and Markets Authority
(‘FSMA’) is required by all natural and legal persons in each case
where the percentage of voting rights in the Company held by such
persons reaches, exceeds or falls below the threshold of 3%, 5%,
10%, and every subsequent multiple of 5%, of the total number of
voting rights in the Company.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com tel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
With its revolutionary and proprietary Idylla™
platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™'s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for COVID-19, Flu,
RSV and sepsis. For more information, visit www.biocartis.com
or follow Biocartis on Twitter @Biocartis_ , Facebook or
LinkedIn.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024